ClinicalTrials.Veeva

Menu

Study of Leukocyte Populations in Patients With Chronic Inflammatory (LIMA)

A

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Sjogren's Syndrome
Chronic Inflammatory Rheumatism
Spondyloarthritis
Systemic Autoimmune Disease
Systemic Lupus Erythematosus
Rheumatoid Arthritis

Treatments

Other: blood sample

Study type

Observational

Funder types

Other

Identifiers

NCT04749875
APHP210093

Details and patient eligibility

About

Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.

Full description

The primary objective is to characterization of the quantitative and qualitative specificities of the different leukocyte sub-populations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases. We will perform an exploratory descriptive study whom primary endpoint will be to assess by FACS the phenotype of the specific leukocyte subsets. In addition, we will characterize the protein and transcriptomic signature associated with the conditions for which we have obtained preliminary data showing their potential involvement in autoimmunity (i.e: IL7 pathway, IFN signature).

Enrollment

1,500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years
  • Patient who did not express his opposition
  • Patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases (pSS, lupus, scleroderma, myositis, unclassified connectivitis) diagnosed according to the usual criteria.
  • Weight> 35 kg

Exclusion criteria

  • Corticosteroid treatment> 10 mg / day
  • Pregnant patient
  • Patients under legal protection
  • Beneficiary of the state medical aid

Trial contacts and locations

1

Loading...

Central trial contact

Xavier MARIETTE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems